Friday, 18 Jan 2019

You are here

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

Researchers from Tel Aviv and Toronto employed a questionnaire-based study, including demographic, fertility, pregnancy outcome, and disease activity questions, was conducted in PsA patients and healthy controls. The inclusion criterion was diagnosis of PsA before at least 1 pregnancy. 

A total of 74 PsA patients and 74 healthy controls were studied and included 151 pregnancies in PsA and 189 pregnancies in controls.  Both groups had similar baseline demographic characteristics.

Overall they found no differences with regard to:

  • mean number of pregnancies, children, and infertility diagnoses
  • live births (76% vs. 76%, P = 0.3),
  • vaginal deliveries (48% vs. 51%, P = 0.6)
  • gestation age (38.5 vs. 38.3, P = 0.3)
  • infant weight at birth (3.4 kg vs. 3.4 kg, P = 0.5)
  • rates of maternal and fetal complications
  • duration and rate of breastfeeding.

More than half of PsA patiens (58%) reported favorable joint activity during pregnancy and 50% reported worsening during the 1st postpartum year.

These data are encouraging for PsA women planning to become pregnant.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.